The US Anti Cancer Drug Market Outlook to 2018 – Demand of Oral Drugs to Drive Growth

The report titled “The US Anti Cancer Drug Market Outlook to 2018 – Demand of Oral Drugs to Drive Growth” provides a comprehensive analysis on the Anti Cancer Drug market in the US covering various aspects such as market size of the industry, market segmentation by Patented and Generic drugs, by type of cancer (blood cancer, breast cancer, lung cancer, pancreatic cancer, colon cancer) and by Oral and Injectable Drugs. The report also provides statistics and information on the government regulations, growth drivers and market shares of major players and brands in the market. The report also entails competitive landscape and profiles of the major players operating in the market. The future projections are included to provide an insight on the prospects in the US Anti Cancer Drug Market.

The US Anti Cancer Drug market is the largest market in the world which has registered a positive growth rate over the period. The rising growth rate can be attributed to an increasing number of drugs being approved by the United States Food and Drug Association along with the increasing number of cancer cases although many major drugs which lost their patent protection has hampered the growth of the market. The US Anti Cancer Drug Market has recorded a 5 year CAGR of 6.50% over the period. The sales of anti cancer drugs in the US grew from USD ~ billion in 2008 to USD ~ billion in 2013.

The Breast Cancer Drug Market is one of largest markets in terms of breast cancer drug sales with a global share of 59% and was valued at USD ~ billion in 2013. The breast cancer drug market though had a busy pipeline but has been mainly driven by sales of three major drugs namely Arimidex, Herceptin and Afinitor in recent years. Pancreatic cancer is one of the most researched segments as it cannot be diagnosed in a time leading to a fall in its survival rates. Avastin, Rituxan, Herceptin and Alimta were among the world’s top selling anti cancer drugs and each recorded sales above USD ~ million in the US in 2013.

The anti-cancer drug market of US is highly fragmented. The major players are continuously adopting diverse strategies in order to maintain their competitive edge especially when it comes to competition from generic drugs. Roche is the largest company in the US in terms of anti cancer drugs sales. The company held a market share of ~% and recorded sales of USD ~ million.

The US Anti Cancer Drug Market is expected to grow over the period at a CAGR of 29.41% with projected sales of USD ~ billion in 2018. It is estimated that the research and development productivity will increase and will trigger the growth in the market. The companies will focus on developing pharmaceutical drugs for personalized healthcare.

Key Topics Covered in the Report:

• The market size of the US anti cancer drug market on the basis of sales, number of drugs in development and number of drugs approved.
• The breast cancer, lung cancer, pancreatic cancer, colon cancer, blood and brain cancer drug market
• Market segmentation of the US anti cancer drug market on the basis of Type of Therapies, Orals and Injectables and by Generic and Patented Drugs
• Government Regulations in the US Anti Cancer Drug Market.
• Competitive landscape and detailed company profiles of the major players operating in the pesticides business in US
• Revenues of Major Players in US Anti Cancer Drugs Market.
• Future outlook and projections of US Anti Cancer Drugs Market, on the basis of anti cancer drug sales in the US.

Browse and Download Report Here – http://www.kenresearch.com/healthcare/pharmaceutical-industry/us-anti-cancer-drug-market-research-report/543-91.html

Contact Person- Ankur Gupta

Contact Email Id- ankur@kenresearch.com

Tags: Breast Cancer Drugs Sales US, Future Prospect Oral Injectable US Cancer, Generic Patent Drug Pipeline US Cancer, Government Regulation US Cancer Drug, Oncology Therapeutic Drugs Industry Trends, US Anti Cancer Drug Market, US Blood cancer drug industry sales